Experiments with cultured mammalian cells represent an in vitro alternative to animal experiments. Fetal calf serum (FCS) is the most commonly used media supplement worldwide. FCS contains a variable mixture of growth factors and cytokines, which support cell proliferation. This undefined nature of FCS is a source of experimental variation, undesired immune responses, possible contaminations, and because of its way of production an ethical concern. Thus, alternative, defined, valid, and reliable media supplements should be characterized in a large number of experiments. Human platelet lysate (hPL) is increasingly appreciated as an alternative to FCS. Since it is unclear whether cells respond differentially to clinically relevant chemotherapeutics inducing replicative stress and DNA damage (Hydroxyurea, Irinotecan), induction of reactive oxygen species (ROS), the tyrosine kinase inhibitor (TKi) Imatinib, and novel epigenetic modifiers belonging to the group of histone deacetylase inhibitors (HDACi), we investigated these issues. Here we show that cancer cells derived from leukemia and colon cancer grow very similarly in culture media with FCS or outdated hPL. Notably, cells have practically identical proteomes under both culture conditions. Moreover, cells grown with FCS or hPL respond equally to all types of drugs and stress conditions that we have tested. In addition, the transfection of blood cells by electroporation can be achieved under both conditions. Furthermore, we reveal that class I HDACs, but not HDAC6, are required for the expression of the panleukemic marker WT1 under various culture conditions. Hence, hPL is a moderately priced substitute for FCS in various experimental settings.
Introduction
On the one hand, cell culture experiments can replace a large number of animal experiments. On the other hand, FCS is a very frequently used additive in cell culture experiments (Gstraunthaler, 2003; Gstraunthaler et al., 2014) . FCS is received from unborn calves older than three months and its collection represents a massive burden for the animals. A needle is inserted into the heart of the fetus to obtain blood, and, since the animals are not under anesthesia, they may suffer pain and discomfort. Additional problems arising with FCS are its potential as a source of contaminations and commonly observed variations in its quality that make FCS an unreliable growth stimulator (Gstraunthaler, 2003; Gstraunthaler et al., 2014) . Moreover, the addition of bovine proteins to human or mouse cell cultures, which are the most frequently used cell types in biomedical research, can lead to artifacts. For example, FCS can blur the identity of freshly isolated pancreatic cancer cells by its ability to excessively trigger otherwise not engaged signaling pathways (Moore et al., 2001) . Moreover, the usage of FCS is incompatible with donations of cells to humans for therapeutic purposes (Barsotti et al., 2013; Doucet et al., 2005) . Due to these concerns, alternative strategies have been considered. While fully recombinant serum replacements are still a cost issue, hPL could be a valid and ethically justifiable option. Human keratinocyte cells, renal epithelial cells, and various leukemic and solid tumor cell lines can be propagated in hPL (Fazzina et al., 2016; Rauch et al., 2011; Baik et al., 2014; Bernardi et al., 2013) . This also holds true for primary human and rodent cells (adipocytes, amniotic fluid stem cells, bone marrow stromal cells, chondrocytes, corneal cells, endothelial cells, keratinocytes, mesenchymal stem cells, monocytes, osteoblasts) (Barsotti et al., 2013; Doucet et al., 2005; Glovinski et al., 2017) . These cell types maintain functionality and signaling in various assays, and some reports even show a better cell proliferation in hPL than in FCS (Bernardi et al., 2013; Glovinski et al., 2017; Barsotti et al., 2013) . Assessment of DNA methylation patterns and the transcriptomes of mesenchymal stromal cells grown in hPL or FCS revealed very similar gene expression patterns under these conditions (Fernandez-Rebollo et al., 2017) .
Furthermore, cells grown in xenogeneic-free hPL are therapeutically useful (Sergeeva et al., 2016; Riis et al., 2016; Thieme et al., 2017) . They could be used for bone regeneration, osteoarthritis, the therapy of stroke, wound healing, and other applications (Tan et al., 2016; Sergeeva et al., 2016; Altaie et al., 2016; Martinelli et al., 2016; Riis et al., 2016; Lykov et al., 2017; Thieme et al., 2017; Leijs et al., 2017) . Indeed, bone marrow stromal cells cultured in hPL are currently tested in a phase I study involving patients with acute ischemic stroke (Shichinohe et al., 2017) . Furthermore, primary cells grown in hPL maintain their genomic integrity and do not form tumors in vivo. This benign cellular phenotype is a key requisite for clinical applications (Tan et al., 2016; Altaie et al., 2016; Martinelli et al., 2016) .
Since fresh hPL is required for clinical use, it has been investigated whether outdated hPL could be anti-apoptotic valid additive to cultivate adipose stem cells. Promisingly, outdated hPL is useful for this purpose (Rauch et al., 2011; Glovinski et al., 2017) and microarray analyses revealed no significant differences in gene expression profiles of cells cultured in fresh or outdated hPL (Glovinski et al., 2017) .
As DNA-damaging chemotherapy is a mainstay of tumor therapy, the question occurred whther cells grown in hPL can respond to such agents. The reactions of leukemic cells HL60, Jurkat) to the DNA-damaging agent Adriamycin are equal in the presence of hPL or FCS as growth additive (Fazzina et al., 2016) . However, it has not been clarified whether FCS and hPL differentiatially affect the DNA damage response that is triggered by a larger number of stimuli and in various cell types.
We assessed whether the reactions of leukemic cells to Imatinib, Hydroxyurea, and HDACi are affected variably by hPL and FCS. We carried out the same tests with colon cancer cells that we treated with Irinotecan or the ROS inducer t-BOOH. Irinotecan inhibits topoisomerase-1 and is a standard drug for colon cancer (Tomicic and Kaina, 2013; Rauch et al., 2018) . We chose these agents based on their clinical relevance and on the fact that inducers of ROS and inhibitors of HDACs occur endogenously (Krämer, 2009; Newman and Verdin, 2014) and may hence be differently present in FCS and hPL. Hydroxyurea inhibits ribonucleotide reductase and can be used to reduce leukemic cell counts (Eklund et al., 2001; Nazha and Gerds, 2016) , Imatinib is used to treat BCR-ABL-positive chronic myeloid leukemia (CML) (Lamontanara et al., 2013) . HDACi are more and more frequently used for leukemia patients and these agents are considered for the therapy of further cancers (Ceccacci and Minucci, 2016; Krämer et al., 2014) . To assess cellular responses at the molecular level, we assessed how Hydroxyurea, Imatinib, and HDACi affect cancer-relevant molecules. These include the transcription factor Wilms tumor-1 (WT1), which is a marker for rapidly proliferating cells and cancer stem cells (Svensson et al., 2007; Makki et al., 2008; Ruan et al., 2018; Pons et al., 2018) , and p53, which is seen as the guardian of the genome (Hofseth et al., 2004) .
We show that leukemic cells and colon cancer cells grow in hPL equally well to slightly better than in FCS. Proteomics followed by mass spectrometry demonstrates in a previously not covered depth that the proteomes of leukemic cells cultured in hPL or FCS are practically identical. Moreover, both cell types respond equally to all stress conditions that we have tested and the growth in hPL renders even hard-to-transfect hematopoietic cells as suitable transfection hosts for siRNAs.
The use of hPL follows the principles of the 3Rs (Replacement, Reduction, Refinement) in order to provide alternatives to animal experiments. Our data suggest that hPL represents a reliable alternative for FCS in cell culture experiments. This could reduce or even replace FCS and thereby the cruel slaughtering of unborn fetuses.
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Materials & Methods
Generation of hPL
The source for hPL were human platelet concentrates in human plasma. They were manufactured by apheresis (aPC), a maximum of 3 days too old to be given to patients, and frozen immediately at -80°C. Manufacturing and specifications of the aPC were in accordance with the German Law (BMJV, 2005) and German Guidelines (Bundesärztekammer, 2017) . We worked with four independent pools of hPL. Each pool was generated by uniting at least 3 platelet units from different donors. This strategy was chosen to avoid donor-dependent variations. Cells were disrupted by freezing (-80°C) and thawing (37°C) cycles. To remove bigger cell fragments, the lysates were centrifuged twice at 2600xg for 20 min. To remove smaller cell debris, the lysates were filtered through a 0.22 µM membrane.
Cell lines and adaptation process
We adapted three human leukemia cell lines (K562, NB4 and MV4-11) as well as HCT116 colon cancer cells to culture media containing 10%, 5%, or 1% FCS (Gibco) and to 5% or 1% hPL. To avoid coagulation, 2 U/ml heparin were added to the media with hPL for K562, NB4 and MV4-11 cells and 4 U/ml were added for HCT116 cells. There was at least an adaption time of 3 weeks before the first experiments. We analyzed cell morphology by light microscopy (Axiovert 35, Carl Zeiss). Growth kinetics were examined by counting. Cell cycle distributions were investigated by flow cytometry (FACS Canto II, BD Biosciences). To assess whether cells grown with hPL can be frozen and thawed for continuous propagation, we froze cells in culture media containing 5% hPL and 10% DMSO at -80°C overnight and then in liquid nitrogen up to about one year. Thawed cells grew similarly to those that had been frozen with 10% FCS. All cells were not longer than three months in culture and regularly tested for mycoplasma contamination. Moreover, cells were authenticated as specified (Pons et al., 2018; Göder et al., 2018) . Poly (ADP-Ribose) Polymerase (PARP1) (556362). Western blot procedure was done as described (Pons et al., 2018) .
Drugs and chemicals
Flow cytometry
The experimental procedure was performed as described (Pons et al., 2018) .
Proteomics
Protein expression patterns were determined by global scale proteomics. Sample preparation and mass spectrometry were done as described (Kiweler et al., 2018) . In short, proteins were separated on a NOVEX NuPage 10% gel, proteins were reduced with DTT, and subsequently alkylated with iodoacetamide (Sigma). In-gel digestion was done with trypsin (Sigma). Peptides were eluted from the gel with acetonitrile, which was removed in a concentrator (Eppendorf) prior to loading on a C18 StageTip. The measurement was performed on a Q Exactive Plus (Thermo), operated in data-dependent acquisition mode with a top10 method. During the 240 min measurement, peptides were eluted with a 2-40% acetonitrile/water gradient. Raw files were processed with MaxQuant (1.5.2.8) (Cox and Mann, 2008) using standard settings, except match between runs and LFQ quantitation were activated. The search was performed against a human Uniprot database (81194 entries).
LFQ normalized intensities were processed using R scripts, including filtering of contaminants and putative false positives. For experiments with replicates, imputation for missing values was performed using the bpca method (Stacklies et al., 2007) for proteins detected in at least one replicate. For non-quantified proteins in any replicate, an arbitrary log2 intensity of 22 was assigned, which is the lowest value across the intensity distribution. Afterwards, mean values were computed for each condition per protein and plotted using the software "R". . 100 pmol siRNA (nontargeting control siRNA-B/sc-44230 (Santa Cruz) or siRNA targeting HDAC6/LQ-003499-00-0002 (Dharmacon) were electroporated with the Amaxa® Nucleofector® II Device (Lonza) using program T-016 for K562 cells and Q-001 for NB4 and MV4-11 cells. Directly after electroporation, cells were incubated for 24 h in 2 mL fresh medium per well. Without any washing steps in between, 2 ml fresh medium were added. Cells were harvested after another 24 h.
Alkaline comet assay (also known as single cell gel electrophoresis assay)
HCT116 cells were seeded at a density of 1x10 6 cells/10 cm dish. 24 h later, cells were treated for 24 h with the topoisomerase-I inhibitor Irinotecan or 10-100 µM t-BOOH 20 min before harvesting. The slides were coated with 1.5% agarose in PBS and dried overnight. 10 µL of a cell suspension with 2x10 6 cells/mL were diluted in 120 µl of 0.5% in PBS low melting point agarose (37°C) and added to the coated slides, which were afterwards covered with cover slips and incubated for 5 min at 4°C. The cover slips were removed sideward, the slides were incubated for 60 min in precooled lysis buffer (pH 10, 2.5 M NaCl, 100 mM EDTA, 10 mM Tris, 1% Sodium lauroylsarcosinate, added immediately before use: 1% Triton X-100 and 10% DMSO) at 4°C. Slides were placed in an electrophoresis chamber and incubated in precooled electrophoresis buffer (300 mM NaOH, 1 mM EDTA, pH>13) at 4°C in the dark for 30 min to allow unwinding of the DNA and the exposure of alkali-labile DNA damage. Electrophoresis was performed for 20 min at 4°C at 23 V and 300 mA in the dark. Subsequently, the slides were 3 times covered with neutralization buffer (0.4 M Tris pH 7.5) for 5 min and shortly immersed in dH2O. They were then fixed in 100% ethanol for 5 min. The slides were dried at RT for at least 2 h. DNA was stained with 50 µl propidium-iodide (stock solution: 50 µg/ml, diluted 1:20 in dH2O). The slides were covered with cover slips and directly measured on a fluorescence microscope (Nikon Instruments). DNA damage (measured as tail intensities) was evaluated with a Comet IV software (Perceptive Imaging). Figure 1A shows how we generated hPL stocks (Fig. 1A) . When we determined the protein concentrations of batches of FCS and hPL, we found that our hPL batch had a slightly higher protein content than the FCS batch (Fig. 1B) . The FCS batch that we had chosen was used by us in previous experiments and gave immaculate results regarding pathogen-free cell proliferation (data not shown).
Results
Generation and characterization of hPL
Adaptation of cancer cells to media with hPL
To find out whether leukemic cells (K562, NB4, MV4-11) could grow in hPL, we compared the morphology and proliferation of cells that we propagated in RPMI containing 10% FCS to growth conditions in RPMI containing 5% hPL or 5% FCS. We performed the same experiment with colorectal cancer cells (HCT116). We analyzed their morphology and growth in DMEM with 10% FCS, 5% hPL, or 5% FCS. After 3 weeks of growth in 5% FCS or 5% hPL, all four cell lines were morphologically indistinguishable from cells grown in 10% FCS (Fig. S1A  1 ) Fig. 2A , S1B 1 ). NB4 cells grew best with 10% FCS and slightly slower with 5% FCS and 5% hPL. MV4-11 cells cultured with 5% hPL grew as good as those with 10% FCS and with 5% FCS such cells grew slower ( Fig. 2A) .
We also tested whether cells grown with hPL can be frozen and thawed for continuous propagation. Indeed, cells that had been frozen in media containing 5% hPL started to grow similarly to cells that had been frozen with 10% FCS (Fig.  S1B 1 and data not shown). Assessment of the cell cycle distributions of leukemic cells and colon cancer cells illustrated no significant differences, except for a trend towards less dead cells in cultures grown with 5% hPL (Fig. 2B) .
Since HCT116 cells are driven by mutant β-catenin (Morin et al., 1997) , we also assessed β-catenin expression in HCT116 cells cultured with hPL or FCS. We found no differences in β-catenin under the two culture conditions (Fig. S1C  1 ) . We additionally assessed the levels of the adhesion molecule and epithelial marker protein E-cadherin, which contributes to the regulation of β-catenin, and of RAC1, which controls epithelial phenotypes (Kimura et al., 2006; Sander and Collard, 1999) . We noted that these proteins were expressed equally well in HCT116 cells grown with FCS or hPL (Fig. S1C  1 ) . We conclude that cell morphology and cell cycle distribution patterns are very similar during growth in FCS or hPL. Fig. 1 : Process of human platelet lysate production A) A minimum of 3 units of enriched platelets were pooled. Platelets were frozen at -80°C and thawed at 37°C thrice. By 2 centrifugation steps (2600xg, 20 min) bigger cell compartments were removed. The lysate was filtered through a 0.22 µM filter to remove smaller compartments. To avoid coagulation, 2 U/ml heparin for suspension cells and 4 U/ml for adherent cells were added. B) The protein concentrations of three independent stocks of FCS and hPL were compared using the Bradford assay, n=3±SD; unpaired, two-tailed Student's t-test, p=0,0008.
Global protein expression of K562 cells grown in medium with FCS or hPL
Although we see no obvious differences between cells cultured in media with 10% FCS or 5% hPL, there could still be alterations at the molecular level. To clarify whether such differences exist, we compared triplicates of K562 cells grown with media plus FCS or hPL with an unbiased proteomic assay. We could detect 4562 proteins with this approach and the heatmap resulting from these analyses shows very similar protein expression patterns (Fig. 3A) . Differences that we noted between the two culture conditions were not significantly higher than differences that we noted within the triplicates. Via a correlation plot, we could show that all samples were equal to at least 98% (Fig. 3B) . Hence, not a single protein was expressed differentially under the two culture conditions (Fig. S2  1 ) .
Reactions of CML cells to Imatinib
Since Imatinib is a standard drug for the treatment of CML carrying BCR-ABL (t9;21) (Lamontanara et al., 2013) , we asssessed whether BCR-ABL-positive K562 cells respond similar to this drug when they are cultured in FCS or hPL. Irrespective of culture conditions in 5-10% FCS or 5% hPL, Imatinib reduced the numbers of BCR-ABL-positive K562 cells in the S and G2/M phases and augmented the numbers of cells in G1 phase (Fig. 4A) . Imatinib has been shown to attenuate the expression of WT1 in BCR-ABL-positive leukemic cells (Svensson et al., 2007) . We could verify this finding and found an equal reduction of WT1 in K562 cells that were grown in 5-10% FCS or 5% hPL and Imatinib (Fig. 4B) . Hence, culture conditions in FCS and hPL equally allow an assessment of the pharmacological effects of Imatinib.
Reactions of leukemic cells to HDAC inhibition and regulation of WT1
Next, we tested if cells cultured in media containing hPL or FCS respond differently to a pharmacological inhibition of HDACs. HDACi become increasingly appreciated as novel anti-cancer drugs. For our analyses we chose Romidepsin, which has been approved by the FDA for the treatment of a subset of hematological malignancies (Ceccacci and Minucci, 2016) . In addition, we used Entinostat and Marbostat-100. Like Romidepsin, Entinostat specifically inhibits the class I HDACs HDAC1, -2, and -3 (Noack et al., 2017) . Marbostat-100 is a novel agent that we have recently developed and characterized as the currently most selective inhibitor of HDAC6 Leonhardt et al., 2018 We treated K562 cells with Romidepsin and Marbostat-100 and found that Romidepsin led to a G1 arrest and a loss of S Phase cells in cultures growing with 10% FCS, 5% FCS, or 5% hPL (Fig. 5A) . Marbostat-100 did not significantly change cell cycle distribution (Fig. 5A) , which is consistent with previous data Leonhardt et al., 2018) .
Using Western Blot, we found an equal inhibition of HDAC1, -2 and -3 by detection of the surrogate marker acetylated Histone H3 (Krämer et al., 2014) under all three conditions. When we tested for the acetylation of Tubulin, which marks inhibition of HDAC6 (Krämer et al., 2014) , we could verify an inhibition of HDAC6 in FCS-and hPL-based culture conditions (Fig. 5B) It has been found that class I HDACi decrease WT1 mRNA and protein expression (Makki et al., 2008) and it has been speculated that inhibition of HDACs might attenuate WT1 via inactivation of the chaperone HSP90 (Bansal et al., 2010) . Western blot analyses revealed that Romidepsin significantly decreased WT1 and caused cleavage of PARP1 in K562 cells cultured in FCS or hPL. Marbostat-100 led to a slight stabilization of WT1 (Fig. 5B-5C ).
To corroborate that leukemia cells respond equally to structurally diverse HDACi in FCS and hPL, we used MV4-11 cells as additional system and treated them with Entinostat as further HDACi. PI-staining showed a comparable cell cycle distribution following treatment, independent from culture conditions in FCS or hPL (Fig. S3A  1 ) . As MV4-11 cells react very sensitive to this agent, we had a closer look on the amount of subG1 fractions, which did also not vary significantly under different culture conditions (Fig. S3B  1 ) . As expected from our data in K562 cells treated with Romidepsin (Fig. 5B) , we could observe a loss of WT1 in MV4-11 cells treated with Entinostat (data not shown).
These data illustrate that cells grown in hPL or FCS respond equally to HDACi and that WT1 is attenuated by class I HDACi but not by an inhibition of HDAC6.
Transfection of cells in media containing hPL or FCS
The genetic manipulation of cultured eukaryotic cells is a mainstay in the search for molecular mechanisms. To assess whether culture conditions based on FCS or hPL have a differential effect on the transfection of leukemic cells with RNAi molecules, we electroporated siRNAs against HDAC6 in K562 (Fig. 5D) , MV4-11, and NB4 cells (Fig. S3C-D  1 ). We could successfully reduce HDAC6 in all three cell lines under both culture conditions (Fig 5D, S3C-D  1 ). As expected from HDAC6 being a tubulin deacetylase (Krämer et al., 2014) , the reduction of HDAC6 led to an accumulation of acetylated tubulin ( Fig  5D, S3C-D  1 ). The levels of WT1 remained constant under such conditions, which supports our data illustrating that a pharmacological inhibition of HDAC6 does not attenuate WT1 expression (Fig 5B-D) . These data illustrate that cells grown in hPL or FCS can be transfected with siRNAs and that WT1 is not a target of HDAC6.
Responses of leukemic and colon cancer cells to replicative stress
We next addressed whether leukemic cells and colon cancer cells grown in FCS or hPL respond equally to Hydroxyurea. This drug is commonly used to cause replicative stress and to clinically reduce high leukemic blast counts (Eklund et al., 2001; Pons et al., 2018; Schäfer et al., 2017; Schneider et al., 2010; Göder et al., 2018) . Consistent with our previous data (Pons et al., 2018; Göder et al., 2018) , Hydroxyurea causes replicative stress in HCT116 cells and NB4 cells rapidly succumb to apoptosis when treated with Hydroxyurea. Hydroxyurea induced the number of NB4 cells in subG1, with cells 10% FCS and 5% hPL responding very similarly to Hydroxyurea. Cells cultured in 5% FCS responded slightly weaker to Hydroxyurea, but such differences did not reach statistical significance (Fig. 6A-B) . In HCT116 cells cultured with 10% FCS, Hydroxyurea induced an 2,7-fold increase of cells in the S Phase. A 2,5-fold increase of cells in S Phase occurred in HCT116 cells cultured with 5% hPL and an 2,9-fold increase of cells in S Phase was seen in HCT116 cells cultured with 5% hPL (Fig. 6C-D We have further reported that Hydroxyurea could trigger an accumulation of phosphorylated and total forms of the tumor suppressor p53 and of the DNA damage marker ɣH2AX in HCT116 cells (Göder et al., 2018) . HCT116 cells in FCS or hPL equally accumulated these proteins in response to Hydroxyurea (Fig. 6E) . We conclude that Hydroxyurea evokes similar cellular responses in cancer cells grown in FCS and hPL.
Responses of colon cancer cells to Irinotecan and t-BOOH
Since Irinotecan is a standard drug for the treatment of colon cancer (Tomicic and Kaina, 2013) , we treated HCT116 cells in medium with 5-10% FCS or 5% hPL with 5 µM Irinotecan for 24-48 h and analyzed them by flow cytometry for cell cycle distribution and subG1 cells.
After 24 h, Irinotecan triggered a strong arrest of cells in the G2/M phase. This arrest was lost at 48 h and the portion of cells in subG1 phase increased (Fig. 7A) . Lower levels of subG1 cells were seen in Irinotecan-treated HCT116 cells that were grown with 5% hPL or 5% FCS compared to cells that were grown with 10% FCS. However, this finding should be appreciated with the notion that the subG1 levels are also lower in resting cells that proliferate with 5% hPL or 5% FCS (Fig. 7A) . Furthermore, the fold induction of the subG1 populations in cells grown with 10% FCS was 2.5, 2.4 for cells grown with 5% FCS, and 2.9-fold in cultures grown with 5% hPL. (Fig. 7B) . Since Irinotecan is a DNA-damaging agent, we tested with the single cell electrophoresis assay/comet assay for a potential impact of the two culture conditions on Irinotecan-induced DNA damage. In order to analyze ROS-induced DNA damage, we applied t-BOOH (Faust et al., 2017) . We exposed cells in 5% hPL or 10% FCS to 20 µM Irinotecan for 24 h hours or to 10 µM or 100 µM t-BOOH for 20 min. We found that Irinotecan as well as t-BOOH evoked equal levels of DNA damage in HCT116 cells grown in FCS or hPL (Fig. 7C-D) .
Taken together, these data show that HCT116 cells that are cultured in hPL or FCS react very similarly to Irinotecan. 
Discussion
We report that cells can be adapted to hPL rapidly. Thus, concerns about a time-consuming adaptation of tumor cells to hPL instead of FCS appear not justified. Data collected with various cell lines and types also provide evidence that cells cultured in media containing hPL or FCS respond equally and reproducibly to various types of cellular stress. It is possible that the cultivation of human cells in human lysate is more appropriate than in bovine serum and therefore causes less basal apoptosis and DNA damage. Further experiments will test this hypothesis. Another concern could be higher costs of hPL over FCS. Depending on the availability of human plasma and possibilities to cooperate with a unit providing (outdated) human plasma, this may or may not be an issue. We would like to stress that the human plasma samples that we used were a few days too old to be given to patients ("waste"). The feasibility to grow cells in human plasma that was outdated for clinical use has coherently been reported by others (Rauch et al., 2011; Glovinski et al., ALTEX preprint published December 14, 2018 doi:10.14573/altex.1809211 9 2017). It is though surprising that the issue of fresh versus outdated has been raised for hPL when it is obvious that FCS is a thawed material that is weeks to months old. Furthermore, we find that 5% hPL is equivalent to 10% FCS regarding cell growth and cellular responses to various drugs, which suggests that hPL is twice as potent as FCS. Our finding that the cells which we tested grow equally well with 5% and 10% FCS further illustrates a worldwide dissipation of FCS with protocols that stipulate the use of 10% FCS. We even noted that K562 cells could grow with only 1% FCS (data not shown), which suggests to save FCS for the cultivation of certain cell types. Our results that leukemic cells and colon cancer cells grown with FCS or hPL respond very equally to chemotherapeutics that cause replicative stress and DNA damage were anticipated. Comparable responses of leukemic cells to the DNA-damaging agent Adriamycin were also seen irrespective of culture in hPL or FCS (Fazzina et al., 2016) . We additionally assessed cellular reactions to Romidepsin, which is currently one of the most potent specific inhibitors of class I HDACs (Noack et al., 2017) . We tested such a condition, because there are endogenous HDACi under physiological conditions (Newman and Verdin, 2014; Krämer, 2009 ). Putative differences in residual endogenous HDACi in FCS or hPL could have altered cellular responses to pharmacological HDACi. However, cells grown with hPL or FCS behave very similarly when treated with Romidepsin.
We further show that an inhibition of class I HDACs, but not of HDAC6, leads to a loss of WT1 in K562 cells grown in FCS or hPL. This finding disfavors that a dependency of WT1 stability on HSP90 (Bansal et al., 2010 ) is linked to HDAC6. Congruent with our data, a lack of interaction between endogenous HDAC6 and overexpressed WT1 has been noted by others in transformed human epithelial kidney cells (Rampal et al., 2014) . Hence, HDAC6 seems not to be a component of the HSP90-WT1 complex that maintains the stability of WT1. Whether or not HDAC6 deacetylates HSP90 is a matter of debate. HSP90 acetylation and its relevance are more complicated than previously anticipated and deduced from correlations (Krämer et al., 2014) . In light of this, Marbostat-100 is a precious tool to analyze whether a protein depends on HDAC6. As for WT1, we could rule out a claimed loss of mutant p53 when HDAC6 is inhibited in pancreatic cancer cells (Schäfer et al., 2017; Stojanovic et al., 2017) . Furthermore, our observation that inhibitors of class I HDACs reduce WT1 is in agreement with the reduction of the WT1 mRNA and an increased proteasomal degradation of WT1 in K562 cells when they are treated with the class I HDACi Entinostat (Makki et al., 2008) . Like PARP1, WT1 is subject to caspase cleavage (Ruan et al., 2018; Pons et al., 2018) . Thus, apoptosis induced by Romidepsin is likely linked to the reduction of WT1.
Our findings demonstrate that hPL is a promising replacement for FCS. We will expand our analyses to further cell types and treatment schedules. 
